- Home Page
- Latest Updates
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Research ADCs
- Research Apoptosis
- Research B cell
- Research BRAF
- Research HDIs
- Research Hedgehog
- Research HER Pathways
- Research VEGF
- Why is the VEGF ligand essential throughout tumor development?
- What are the strategies for inhibiting the VEGF pathway?
- What are the effects of direct VEGF ligand inhibition?
- Why is continued VEGF inhibition important?
- Why do tumors progress?
- The role of VEGF across tumor types
- Slide decks and videos
- Glossary
- Clinical Trials
- Resources
- Contact Us
Biooncology R-VEGF
Related Resources for this page:
- Clinical Trials
- Future Directions
- Antibody-Drug Conjugates
- Emerging therapeutic options
- Emerging therapeutic options
- HER Signaling
- High VEGF expression
- Hypoxic tumor environment promotes angiogenesis
- MVD and progression
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- Summary
- Summary
- VEGF and MVD
- VEGF in bladder cancer
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis
- VEGF and prognosis in multiple myeloma
- VEGF and prognosis in pancreatic cancer
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF expression in multiple myeloma
- VEGF in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF, MVD, and metastases in gastric carcinoma
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Emerging therapeutic options
- Emerging therapeutic options
- HER Signaling
- High VEGF expression
- Hypoxic tumor environment promotes angiogenesis
- MVD and progression
- Emerging therapeutic options
- Obinutuzumab (GA101)
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- Summary
- Summary
- VEGF and MVD
- VEGF in bladder cancer
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis
- VEGF and prognosis in multiple myeloma
- VEGF and prognosis in pancreatic cancer
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF expression in multiple myeloma
- VEGF in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF, MVD, and metastases in gastric carcinoma
- Non-Antibody Biologics
- Apoptosis
- High VEGF expression
- Hypoxic tumor environment promotes angiogenesis
- MVD and progression
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- Summary
- Summary
- Extrinsic pathway
- What are the strategies for inhibiting the VEGF pathway?
- VEGF and MVD
- VEGF in bladder cancer
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis
- VEGF and prognosis in multiple myeloma
- VEGF and prognosis in pancreatic cancer
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF expression in multiple myeloma
- VEGF in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF, MVD, and metastases in gastric carcinoma
- Targeted Small Molecules
- Apoptosis
- Apoptotic pathways
- The Bcl-2 family
- Apoptosis
- Emerging therapeutic options
- Emerging therapeutic options
- Resisting apoptosis
- Gastric Cancer
- HER1/EGFR as a therapeutic target
- High VEGF expression
- Hypoxic tumor environment promotes angiogenesis
- MEK Inhibitor (GDC-0973)
- MVD and progression
- Emerging therapeutic options
- PI3K Inhibitor (GDC-0941)
- Reactivating apoptosis
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- Summary
- Summary
- PI3K/Akt/mTOR Signaling
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- VEGF and MVD
- VEGF in bladder cancer
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis
- VEGF and prognosis in multiple myeloma
- VEGF and prognosis in pancreatic cancer
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF expression in multiple myeloma
- VEGF in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF, MVD, and metastases in gastric carcinoma
- Traditional Monoclonal Antibodies
- Anti-EGFL7
- B-cell Surface Proteins
- Glossary
- Direct cell death
- Emerging therapeutic options
- Emerging therapeutic options
- Gastric Cancer
- HER Signaling
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- High VEGF expression
- Hypoxic tumor environment promotes angiogenesis
- MVD and progression
- Emerging therapeutic options
- Obinutuzumab (GA101)
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- Summary
- Summary
- Summary
- Angiogenic Signaling
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- VEGF and MVD
- VEGF in bladder cancer
- VEGF in gastric cancer
- VEGF in pancreatic cancer
- VEGF and prognosis
- VEGF and prognosis in multiple myeloma
- VEGF and prognosis in pancreatic cancer
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- VEGF expression in gastric cancer
- VEGF expression in multiple myeloma
- VEGF in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF, MVD, and metastases in gastric carcinoma
- Antibody-Drug Conjugates
Video
Full VEGF & angiogenesis
View video now
Slides
The role of VEGF in colorectal cancer (CRC)
View SlidesLinks
The relationship between angiogenesis and tumor cell apoptosis in colorectal cancer
Angiogenesis is 1 of the 6 cellular transformations that lead to malignant growth1,2
Hanahan and Weinberg proposed that most, if not all, human cancers share 6 acquired capabilities that enable malignant growth. These traits include self-sufficiency in growth signals, insensitivity to growth-inhibiting signals, evasion of apoptosis, tissue invasion and metastasis, limitless replicative potential, and sustained angiogenesis. This last capability, angiogenesis, enables tumor cells to obtain the oxygen and nutrients they need to grow, and is regulated by a complex system of cellular signals.1
Reprinted from Hanahan D, Weinberg RA, "Hallmarks of Cancer: The Next Generation" in Cell, 2011;144:646-674, with permission from Elsevier.
Resisting cell death and inducing angiogenesis are 2 of the 6 "Hallmarks of Cancer" described by Hanahan and Weinberg.1,2 These 2 tumor traits are interrelated through a number of complex cellular mechanisms, including Bcl-2, and other cell death–regulating pathways. In an analysis of 44 adenomas and 26 carcinomas, Aotake and colleagues observed a significant correlation between tumor cell apoptosis and angiogenesis. The investigators noted that microvessel density gradually increased as cancer progressed (ie, from low dysplasia to high dysplasia to carcinoma). Further analysis revealed an inverse relationship between microvessel density and the apoptotic index (ie, the percentage of apoptotic cells in a given specimen of tumor cells). The authors concluded that angiogenesis is a key factor in colorectal cancer progression and, further, that angiogenesis may cause a reduction in tumor cell apoptosis over the course of development.3
Relative VEGF expression levels in Dukes' Stage C colon cancer and surrounding mucosa4
Kuniyasu et al measured VEGF expression in colon cancer. Median intensity of VEGF expression was quantified in distant mucosa (control), adjacent mucosa, and tumor tissue, with a value of 100 assigned to the control. Adjacent mucosa and tumor tissue had comparatively higher intensities of VEGF expression, with values of 209 and 227, respectively (P<0.0001).4
Adapted from Kuniyasu 2000.
VEGF: expressed at elevated levels in malignant cells
In an analysis of colon cancer surgical specimens, Kuniyasu and colleagues found elevated vascular endothelial growth factor (VEGF) levels in tumors and adjacent mucosa compared with distant mucosa in all of Dukes' Stage C (n=34) carcinomas. In Dukes' Stage B (n=40) carcinomas, elevated VEGF levels were observed in all tumors compared with distant mucosa.4
References:
- 1.
- Hanahan D, Weinberg RA. Cell. 2000;100:57-70.
- 2.
- Hanahan D, Weinberg RA. Cell. 2011;144:646-674.
- 3.
- Aotake T, Lu CD, Chiba Y, et al. Clin Cancer Res. 1999;5:135-142.
- 4.
- Kuniyasu H, Yasui W, Shinohara H, et al. Am J Pathol.
2000;157:1523-1535.